|
| |
|
 | |
           
|  |

|
| PS: The quotes after 2017-05-12 are still temporary and may have for that reason the Open values wrong until furter updates... Change to Biogen Idec Inc. Static Chart |
Biogen Idec Inc. - [Ticker: BIIB] | | Last Trade | 315.51 | Last Trade Time | 2017-11-01 - 19:35:00 | Variation | +3.85 (+1.24%) | Open | 312.75 | High | 319.95 | Low | 311.57 | Volume | 1,047,609 | Average Volume (3m) | 0 | Yield | | Bid / Ask | 315.47 x 300 - 315.59 x 200 | Former Close | 311.66 | 52 Week Range | [0.00 - 0.00] | PER | 0.00% | EPS | 0.00 | Ex-Dividend Date | | Dividend Payment | | Market Capitalization | 0 | 1 Year Price-Target | 0.00 | Note: The data may have some minutes of delay. |
|
News about Biogen Idec Inc. [BIIB]: (ordered by relevance)
| Auto-Injectors Market Demand Overview, Growth Innovation, Latest ... Digital Journal
Multiple Sclerosis Therapeutics Market to Reach US$ 24.4 Billion ... Medgadget
Bleeding Disorders Treatment Market Market Overview Highlighting ... Digital Journal
Biogen Inc. Agrees to Pay $900 Million to Settle Allegations Related ... Department of Justice
Auto-Injectors Market Demand : Mylan, BD, Johnson & Johnson ... SleterFC.com
Biogen agrees to $900 million drug kickback settlement on eve of trial Reuters
Oncology Biosimilars Market, Oncology Biosimilars Market analysis ... Digital Journal
DOJ Resolves Michael Bawduniak against Biogen Inc. FCA Lawsuit The National Law Review
Benefits Biogen
Biogen CEO Plots A Slow Return To Growth As Revenue Set To ... Scrip
Biogen International Biogen
Biosimilars Biogen
Responsibility Biogen
Environment Biogen
2021 Year in Review: Our Commitment to Corporate Responsibility Biogen
Autoimmune Treatment Global Market Report 2023 Yahoo Finance
Alzheimer's Drug Slows Cognitive Decline in Key Study The New York Times
Global Dementia Drugs Market Size To Worth USD 36.7 Billion By ... GlobeNewswire
Autoimmune Treatment Global Market Report 2023 GlobeNewswire
Chronic Lymphocytic Leukemia Therapeutics Market Growth ... Digital Journal
Verastem Oncology Appoints Rob Gagnon to Board of Directors Business Wire
Biogen Drops Idec From Name - WSJ The Wall Street Journal
Biogen Idec: A Great Company, But Not An Alpha Opportunity ... Seeking Alpha
Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday Forbes
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix FierceBiotech
Some Biogen Idec employees are taking the `disco bus? to work in Cambridge Boston.com
Spinal Muscular Atrophy (SMA) Treatment Market is poised to grow ... Digital Journal
Pricing Strategy For New Anti-Alzheimer's Drug Puts Access ... Life Science Leader Magazine
Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent ... Genetic Engineering & Biotechnology News
Biogen Idec provides coach commuting for suburban workers The Boston Globe
Atara Biotherapeutics Announces Changes to Its Board of Directors Business Wire
Hybrid and vaccine?induced immunity against SAR?CoV?2 in MS ... onlinelibrary.wiley.com
BPGbio Announces Appointments to its Leadership Team to ... Business Wire
Biogen Idec grabs Convergence, neuropathic pain portfolio in $675 ... FierceBiotech
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells ... pnas.org
Canada OKs Biogen Idec drug for treatment of hemophilia B The Boston Globe
Exclusive: Biogen prices hemophilia drug on par with older therapies Reuters
Trend Innovations Holding, Inc. Appoints Kenneth L. Waggoner as ... GlobeNewswire
Current and future players in the lupus market Pharmaceutical Technology
Oncology Biosimilars Market Detailed In New Research Report ... Digital Journal
Why Biogen's Alzheimer's drug Aduhelm is so controversial CNBC
Biogen Idec Opens New RTP Facility Business Wire
Will Biogen Stock Rise After The Recent 6% Fall? Forbes
Propionate exerts neuroprotective and neuroregenerative effects in ... pnas.org
Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera Reuters
Multiple Sclerosis Therapeutics Market Outlook, Opportunities and ... Digital Journal
GV20 Therapeutics Announces Appointment of Three Advisers Business Wire
Biosimilars Market is Anticipated to Grow at a CAGR of 14.1% from ... GlobeNewswire
European neurologists expect Biogen Idec's Tecfidera to be ... The Pharma Letter
Aduhelm | ALZFORUM Alzforum
Biogen, MedRhythms team on multiple sclerosis music-based digital ... FierceBiotech
FDA approves Biogen Idec?s multiple sclerosis drug The Boston Globe
FDA Approves Biogen Idec's ALPROLIX?, the First Hemophilia B ... Business Wire
Biogen to pay Forward Pharma $1.25 billion to protect MS drug Reuters
FDA approves new Biogen MS drug The Boston Globe
UPDATED: Germany gives an initial 'no additional benefit' on ... FiercePharma
Special Report: Biogen Idec and Facet?Following the Money Genetic Engineering & Biotechnology News
Biogen confirms HQ move to Weston - Boston Business Journal Boston Business Journal
Clinical Mass Spectrometry Market is expected to generate revenue ... Digital Journal
Biogen Agrees to Pay $22 Million to Resolve Allegations that it Paid ... Department of Justice
A Complete Study Exploring Vacuum Pumps Market Emerging ... Digital Journal
AstraZeneca, Cephalon, and Biogen Idec to Pay $55.5 Million to ... PR Newswire
Biogen Idec isn't planning on leaving its Weston complex anytime ... Boston Business Journal
Leon Kircik, MD, FAAD: The Evolving Acne Arsenal Dermatology Times
Samsung Biologics Completes Full Acquisition of Samsung Bioepis JD Supra
An Increase In Investments In The R&D Of Autoimmune Disease ... GlobeNewswire
Wallpaper Market to Witness Huge Growth in Coming Years With ... Digital Journal
Leaders in health, banking elected to join UC Santa Cruz ... news.ucsc.edu
Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen FierceBiotech
Biogen Stock Forecast, Price & News (NASDAQ:BIIB) MarketBeat
Gene Network Sciences Announces Drug Development ... Pharmaceutical Online
Cellular and Humoral Immunity to SARS?CoV?2 Infection in Multiple ... onlinelibrary.wiley.com
Movers & Shakers, March 11 | BioSpace BioSpace
Medical Microcontrollers Market Set to Reach Valuation of USD ... GlobeNewswire
ClearBridge $2 Stock Buy Reaches $480 on Alzheimer's Drug Bloomberg
Carl Icahn Takes On Biogen Idec ... Again CNBC
Biogen Halts Anti-CD40 Ligand Monoclonal Antibody Trials Pharmaceutical Online
Failed ALS study haunts Biogen in lawsuit from unhappy partner FierceBiotech
Use of Research Tools May Expose Companies to Patent ... IPWatchdog.com
U.S. judge rules against Perrigo over $1.9 billion Irish tax liability Reuters
Drugs group Perrigo hit with ?1.64bn Irish back tax bill Financial Times
Wood Waste Management And Recycling Market Size Will Observe ... Digital Journal
The price is right for patient-switching on Biogen's new hemophilia ... FiercePharma
Bioverativ: Advancing Hemophilia Treatments (NASDAQ:BIVV) Seeking Alpha
CORRECTED - Biogen reports six new PML cases with Tysabri Reuters
Landos Biopharma Announces Appointment of Fabio Cataldi, MD ... GlobeNewswire
FDA adds warning to Tecfidera label after patient death The Pharma Letter
How Biogen Makes Money: Treatments for Neurological Disorders Investopedia
New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price Multiple Sclerosis News Today
Biogen expands executive team at spin-out Bioverativ The Pharma Letter
Tysabri: The Model For Facing A Drug Safety Crisis Forbes
FDA Approves Rituximab for Multiple Pediatric Cancers Medscape
Top 15 Drug Launch Superstars FiercePharma
COVID?19 in multiple sclerosis patients: susceptibility, severity risk ... onlinelibrary.wiley.com
Sanofi to Acquire Biogen Spin-Off in $11.6-Billion Deal BioPharm International
The top 10 best-selling multiple sclerosis drugs of 2013 FiercePharma
Patenting Diagnostics and Biomarkers Six Years After Mayo Lexology
Ceres Policy Network Business for Innovative Climate and Energy ... Ceres
A Better Interferon? Multiple Sclerosis Discovery Forum
Alkahest Announces Positive Top-line Data From Phase 2 Study In ... Clinical Leader
| For more news about Biogen Idec Inc. click here: Biogen Idec Inc. News |
|
Website Width: Background image: |
|  | |
|
|